patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug · oligosaccharide

save

HEPARIN SODIUM

Marketedupdated 2mo ago

by $PFE PFIZER INC🔗 ChEMBL

Approved

community read0 votes

Oligosaccharide drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 7 investigational indications.

indications

investigational

Atrial Fibrillation

targets

Antithrombin-III

all catalysts(53)

approval · 53

view all 53 catalysts →

News(0)

no news has mentioned this drug yet

brand

HEPARIN SODIUM

trade names

Heparin lock flush, Heparin sodium, Heparin sodium component of defencath, Heparin sodium component of embolex, Heparin sodium preservative free, Lipo-hepin

generic

HEPARIN SODIUM

MOA

12.1 Mechanism of Action Heparin interacts with the naturally occurring plasma protein, Antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin III, thereby inhibiting the activated coagulation factors involved in the clotting sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and larger amounts inhibit thrombin (Factor IIa). Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin does not have fibrinolytic activity; therefore, it will not lyse existing clots.

phase

marketed

HEPARIN SODIUM

indications

targets

all catalysts(53)

News(0)

Report a data issue

🐶 often sniffed alongside

comments(0)

Trials studying HEPARIN SODIUM